Total GLP-1-HS ELISA Kit

Cat. No.	Size	Price
YK161	96 wells (1 kit)	$729,1

Technical Data

We recommend switching to the alternative product YK161 (GLP-1 EIA Kit) as YK160 (Total GLP-1 HS ELISA) has been discontinued.

Type

Sandwich ELISA

Description

This EIA kit is used for quantitative determination of obestatin in human plasma and serum samples. It has various advantages, such as highly specific and sensitive quantification, no influences with other body fluids or physiological active substances and unnecessity of sample pretreatment. Human obestatin standard of this kit is a highly purified synthetic product (purity: higher than 99%).

Applications

Plasma

Sample Requirements

25 μL/well

Shipping

2 ~ 8°C. Upon receipt, store the product at the temperature recommended below, all components are stable until the expiration date (see label on the vial).

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

1.24 – 300 pM

Intra-assay (Within-Run)

CV = 1.98% – 5.43%

Inter-assay (Run-to-Run)

CV =2.21% – 3.84%

Spiking Recovery

100,40%

Dilution Linearity

101,30%

Summary

Features

The kit for determination of total GLP-1 in rat and human plasma and culture supernatant sample is based on the sandwich enzyme immunoassay. During first immune incubation, GLP-1(7-36)amide in standards or in samples bind to the rabbit anti GLP-1(7-36)amide antibody, which is coated on the surface of the microtiter plate. After incubation and plate washing, labeled antibody solution (biotinylated rabbit anti GLP-1(7-36)amide polyclonal antibody) is added to bind to the antibody-antigen complex. Then, HRP labeled streptoavidin (SA-HRP) is added to form antibody-antigen-biotinylated antibody complex. Finally, HRP enzyme activity is determined by 3,3’,5,5’-Tetramethylbenzidine (TMB) and the concentration of total GLP-1 is calculated.

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation

Summary

GLP-1 is a peptide hormone from the intestinal mucosa, which is produced from its precursor, proglucagon by post transnational processing. The mammalian proglucagon 1) is synthesized in the neuroendocrine L-cell of the intestine and the alpha-cells of the pancreas.

Product References (10)

References

Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118(1-2):89-97. doi: 10.1016/j.regpep.2003.11.003. PubMed PMID: 14759561. See more on PubMed
Näslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellström PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91(3):439-46. doi: 10.1079/BJN20031064. PubMed PMID: 15005830. See more on PubMed
Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):430-41. doi: 10.1002/dmrr.328. PubMed PMID: 12469357. See more on PubMed
Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49(4):611-7. doi: 10.2337/diabetes.49.4.611. PubMed PMID: 10871199. See more on PubMed
Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15(11):937-45. doi: 10.1002/(SICI)1096-9136(1998110)15:11<937::AID-DIA701>3.0.CO;2-0. PubMed PMID: 9827848. See more on PubMed
Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64(3):367-72. doi: 10.1016/s0031-9384(98)00089-4. PubMed PMID: 9748106. See more on PubMed
Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43(4):535-9. doi: 10.2337/diab.43.4.535. PubMed PMID: 8138058. See more on PubMed
Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265(14):8001-8. PubMed PMID: 1692320. See more on PubMed
Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3(1):1-8. PubMed PMID: 1707301. See more on PubMed
Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259(22):14082-7. PubMed PMID: 6094539. See more on PubMed

Summary References (11)

References to Glucagon-Like Peptide-1

Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64 (3):367-72
Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259 (22):14082-7
Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11 (1):90-4
Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18 (6):430-41
Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265 (14):8001-8
Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91 (3):439-46
Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118 (1-2):89-97
Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15 (11):937-45
Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43 (4):535-9
Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49 (4):611-7
Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3 (1):1-8

Total GLP-1-HS ELISA Kit

Type

Description

Applications

Sample Requirements

Shipping

Storage/Expiration

Calibration Range

Intra-assay (Within-Run)

Inter-assay (Run-to-Run)

Spiking Recovery

Dilution Linearity

Features

Research topic

Summary

References

References to Glucagon-Like Peptide-1

Instructions for Use (RUO)

Safety Information (RUO)

Find documents for the lot

Total GLP-1-HS ELISA Kit

Type

Description

Applications

Sample Requirements

Shipping

Storage/Expiration

Calibration Range

Intra-assay (Within-Run)

Inter-assay (Run-to-Run)

Spiking Recovery

Dilution Linearity

Features

Research topic

Summary

References

References to Glucagon-Like Peptide-1

By Research Topic

By Molecule

By Technical Data

Instructions for Use (RUO)

Safety Information (RUO)

Find documents for the lot